Rhumbline Advisers Has $1.94 Million Position in NxStage Medical, Inc. (NXTM)

Rhumbline Advisers increased its position in shares of NxStage Medical, Inc. (NASDAQ:NXTM) by 0.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 77,384 shares of the medical device company’s stock after purchasing an additional 115 shares during the quarter. Rhumbline Advisers owned approximately 0.12% of NxStage Medical worth $1,940,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in NxStage Medical by 1.9% during the first quarter. FMR LLC now owns 7,482,201 shares of the medical device company’s stock worth $200,747,000 after purchasing an additional 137,399 shares during the last quarter. Vanguard Group Inc. boosted its stake in NxStage Medical by 8.5% in the first quarter. Vanguard Group Inc. now owns 5,273,762 shares of the medical device company’s stock valued at $141,495,000 after acquiring an additional 412,233 shares during the last quarter. BlackRock Inc. boosted its stake in NxStage Medical by 38,360.4% in the first quarter. BlackRock Inc. now owns 4,413,326 shares of the medical device company’s stock valued at $118,408,000 after acquiring an additional 4,401,851 shares during the last quarter. Victory Capital Management Inc. boosted its stake in NxStage Medical by 6.8% in the first quarter. Victory Capital Management Inc. now owns 1,414,099 shares of the medical device company’s stock valued at $37,940,000 after acquiring an additional 89,830 shares during the last quarter. Finally, OppenheimerFunds Inc. boosted its stake in NxStage Medical by 54.7% in the first quarter. OppenheimerFunds Inc. now owns 1,284,754 shares of the medical device company’s stock valued at $34,470,000 after acquiring an additional 454,147 shares during the last quarter. Institutional investors and hedge funds own 93.20% of the company’s stock.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 7,000 shares of NxStage Medical stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $22.98, for a total transaction of $160,860.00. Following the transaction, the president now owns 82,903 shares of the company’s stock, valued at $1,905,110.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Matthew W. Towse sold 4,300 shares of NxStage Medical stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of $23.29, for a total transaction of $100,147.00. Following the transaction, the senior vice president now directly owns 29,637 shares in the company, valued at approximately $690,245.73. The disclosure for this sale can be found here. Insiders have sold 50,400 shares of company stock worth $1,386,536 in the last ninety days. Insiders own 4.70% of the company’s stock.

A number of research firms have weighed in on NXTM. William Blair cut shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a research note on Monday, August 7th. Zacks Investment Research upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Thursday, August 10th. Leerink Swann cut shares of NxStage Medical from an “outperform” rating to a “market perform” rating and boosted their target price for the company from $28.00 to $30.00 in a research note on Tuesday, August 22nd. Craig Hallum began coverage on shares of NxStage Medical in a research note on Tuesday, June 27th. They issued a “buy” rating and a $32.00 target price on the stock. Finally, Canaccord Genuity cut shares of NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 target price on the stock. in a research note on Monday, August 7th. One research analyst has rated the stock with a sell rating and nine have issued a hold rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $30.25.

COPYRIGHT VIOLATION NOTICE: “Rhumbline Advisers Has $1.94 Million Position in NxStage Medical, Inc. (NXTM)” was posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://transcriptdaily.com/2017/09/17/rhumbline-advisers-has-1-94-million-position-in-nxstage-medical-inc-nxtm.html.

NxStage Medical, Inc. (NXTM) opened at 27.79 on Friday. NxStage Medical, Inc. has a 1-year low of $20.45 and a 1-year high of $30.80. The stock’s market capitalization is $1.83 billion. The firm has a 50-day moving average of $27.58 and a 200-day moving average of $25.90.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The business had revenue of $92.20 million for the quarter, compared to the consensus estimate of $96.47 million. During the same quarter in the previous year, the firm earned ($0.03) earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. Equities analysts expect that NxStage Medical, Inc. will post ($0.05) EPS for the current fiscal year.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply